ATE480569T1 - Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen - Google Patents

Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen

Info

Publication number
ATE480569T1
ATE480569T1 AT07766524T AT07766524T ATE480569T1 AT E480569 T1 ATE480569 T1 AT E480569T1 AT 07766524 T AT07766524 T AT 07766524T AT 07766524 T AT07766524 T AT 07766524T AT E480569 T1 ATE480569 T1 AT E480569T1
Authority
AT
Austria
Prior art keywords
independently
polypeptide
integer
amino acid
activated ras
Prior art date
Application number
AT07766524T
Other languages
English (en)
Inventor
Coupade Catherine De
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis filed Critical Cellectis
Application granted granted Critical
Publication of ATE480569T1 publication Critical patent/ATE480569T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07766524T 2006-06-12 2007-06-08 Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen ATE480569T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290952A EP1867661A1 (de) 2006-06-12 2006-06-12 Zusammensetzungen und Verfahren zur Einschleusung von Anti-aktivierten-Ras-Antikörpern in Zellen
PCT/IB2007/001546 WO2007144730A1 (en) 2006-06-12 2007-06-08 Compositions and methods for delivering anti-activated ras antibodies into cells

Publications (1)

Publication Number Publication Date
ATE480569T1 true ATE480569T1 (de) 2010-09-15

Family

ID=37102144

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07766524T ATE480569T1 (de) 2006-06-12 2007-06-08 Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen

Country Status (7)

Country Link
US (1) US20120141478A1 (de)
EP (2) EP1867661A1 (de)
AT (1) ATE480569T1 (de)
DE (1) DE602007009116D1 (de)
DK (1) DK2044125T3 (de)
ES (1) ES2352321T3 (de)
WO (1) WO2007144730A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
WO2012162628A2 (en) * 2011-05-25 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of ras oncoproteins
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
PE20200697A1 (es) 2017-06-22 2020-06-16 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso
WO2019014190A1 (en) 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF
EP3652195A4 (de) 2017-07-10 2021-08-04 SRI International Peptidsaporinkonjugat zur behandlung von krebs
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
JP7604376B2 (ja) 2018-12-28 2024-12-23 バーテックス ファーマシューティカルズ インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US8003595B2 (en) * 2000-03-01 2011-08-23 Cellectis Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
EP1565495A2 (de) * 2002-11-15 2005-08-24 Medical Research Council Antikörper gegen aktivierte ras-proteine
WO2005016960A2 (en) * 2003-08-14 2005-02-24 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei

Also Published As

Publication number Publication date
EP2044125B1 (de) 2010-09-08
EP1867661A1 (de) 2007-12-19
US20120141478A1 (en) 2012-06-07
WO2007144730A1 (en) 2007-12-21
DK2044125T3 (da) 2011-01-10
DE602007009116D1 (de) 2010-10-21
EP2044125A1 (de) 2009-04-08
ES2352321T3 (es) 2011-02-17

Similar Documents

Publication Publication Date Title
DE602007009116D1 (de) Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen
CY1122476T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι)
AR068566A1 (es) Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
WO2008060331A3 (en) Antibodies to sars coronavirus
CY1118845T1 (el) Πρωτεϊνες συνδεσης αντιγονου υποδοχεα α il-17
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
WO2008031133A3 (en) Borrelia antigens
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ
EP2532365A4 (de) Pharmazeutische zusammensetzung zur behandlung und/oder prävention von krebs
CY1115572T1 (el) Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου
JOP20140120B1 (ar) إستعمال جديد لمركب اي ال -1 بيتا
DK1347730T3 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
WO2008080082A3 (en) Methods for modulating set and uses thereof
ME02602B (de) Gerinnungshemmende gegenmittel
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
EA201300130A1 (ru) Способ лечения болезни альцгеймера

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2044125

Country of ref document: EP